

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated October 27, 2022 (the “**Prospectus**”) issued by LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.\* (樂普心泰醫療科技(上海)股份有限公司) (the “**Company**”). This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law or to any U.S. person (as defined in Regulation S under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been and will not be registered under the U.S. Securities Act or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There has not been and it is not currently intended for there to be any public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.



**LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.\***

**樂普心泰醫療科技(上海)股份有限公司**

*(a joint stock company incorporated in the People’s Republic of China with limited liability)*

**(Stock Code: 2291)**

**STABILIZING ACTIONS,  
END OF STABILIZATION PERIOD  
AND LAPSE OF OVER-ALLOTMENT OPTION**

**STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

The Company announces that the stabilization period in connection with the Global Offering ended on Thursday, December 1, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Further information in relation to the stabilization actions undertaken by China International Capital Corporation Hong Kong Securities Limited, the Stabilizing Manager, or any person acting for it, during the stabilization period, is set out below.

## **LAPSE OF OVER-ALLOTMENT OPTION**

The Company further announces that the Over-allotment Option had not been exercised by the Sole Global Coordinator and the Sole Overall Coordinator (on behalf of the International Underwriters) during the stabilization period and lapsed on Thursday, December 1, 2022. Accordingly, no Shares were or will be issued under the Over-allotment Option.

## **STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Thursday, December 1, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, the Stabilizing Manager, or any person acting for it, during the stabilization period are set out below:

- (i) over-allocations of an aggregate of 3,368,000 H Shares under the International Offering, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (ii) successive purchases of an aggregate of 3,368,000 H Shares in the price range of HK\$27.50 to HK\$29.15 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%) on the market during the stabilization period, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The last purchase made by the Stabilizing Manager or any person acting for it, on the market during the course of the stabilization period was on Wednesday, November 30, 2022 at the price of HK\$29.15 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%).

## **LAPSE OF OVER-ALLOTMENT OPTION**

The Company further announces that the Over-allotment Option had not been exercised by the Sole Global Coordinator and the Sole Overall Coordinator (on behalf of the International Underwriters) during the stabilization period and lapsed on Thursday, December 1, 2022. Accordingly, no Shares were or will be issued under the Over-allotment Option.

## **PUBLIC FLOAT**

The Company has applied, and the Stock Exchange has granted, a waiver from strict compliance with the requirements of Rule 8.08(1)(a) of the Listing Rules subject to conditions imposed by the Stock Exchange. The Company continues to comply with the minimum public float percentage prescribed in the conditions imposed in the waiver granted by the Stock Exchange from strict compliance with Rule 8.08(1)(a) of the Listing Rules.

By order of the Board  
**LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.\***  
**Chen Juan**  
*Chairman of the Board and Executive Director*

People's Republic of China, December 1, 2022

*As at the date of this announcement, the board of directors of the Company comprises (i) Ms. Chen Juan as chairman and executive Director, (ii) Ms. Zhang Yuxin as executive Director; (iii) Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors; and (iv) Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng and Mr. Liu Daozhi as independent non-executive Directors.*

\* *The Company is a registered non-Hong Kong company as defined in the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

\* *For identification purposes only*